Efficacy and Safety of ETX-018810 for the Treatment of Diabetic Peripheral Neuropathic Pain

PHASE2CompletedINTERVENTIONAL
Enrollment

167

Participants

Timeline

Start Date

November 9, 2020

Primary Completion Date

February 9, 2022

Study Completion Date

February 18, 2022

Conditions
Diabetic Peripheral Neuropathic PainDiabetic Peripheral Neuropathy
Interventions
DRUG

ETX-018810

Study Drug

DRUG

Placebo

Matching Placebo

Trial Locations (22)

10036

IMA Clinical Research, New York

14221

Upstate Clinical Research Associates, Williamsville

30265

Better Health Clinical Reseach, Newnan

32159

Charter Research, Lady Lake

33155

Cordova Research Institute, Miami

33186

Coral Research Clinic Corp, Miami

36609

Delta Clinical Research, Mobile

45417

Midwest Clinical Research Center, Dayton

47714

Medisphere Medical Research Center, Evansville

65810

StudyMetrix Research LLC, City of Saint Peters

78731

FutureSearch Trials of Neurology, Austin

84015

Alpine Research Organization, Clinton

84107

Jean Brown Research, Salt Lake City

Wasatch Clinical Research LLC, Salt Lake City

85053

Arizona Research Center, Phoenix

89119

Alliance for Multispeciality Research LLC, Las Vegas

91978

Encompass Clinical Research, Spring Valley

92780

Diabetes Research Center, Tustin

93710

Neuro-Pain Medical Cneter, Fresno

98007

Northwest Clinical Research Center, Bellevue

06517

Chase Medical Research LLC, Hamden

08009

Hassman Research Institute, Berlin

Sponsors
All Listed Sponsors
lead

Eliem Therapeutics (UK) Ltd.

INDUSTRY